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Summary
Background and aims Vitamin D deficiency is fre-
quent in patients with cirrhosis. The aims of this study
were to evaluate the relation of vitamin D status to
portal hypertension, degree of liver dysfunction and
survival.
Methods Patients with cirrhosis who have been tested
for 25-OH-vitamin D levels were retrospectively in-
cluded. Vitamin D deficiency was defined as 25-OH-
vitamin D levels <10 ng/ml. Child–Pugh score, model
for end-stage liver disease (MELD) and available hepa-
tic venous pressure gradient (HVPG) were recorded.
Mortality was documented during follow-up.
Results A total of 199 patients were included. Preva-
lence of vitamin D deficiency (<10ng/ml) was 40%
(79/199), with 14% in Child–Pugh stage A, 39% in
Child–Pugh stage B and 47% in Child–Pugh stage C
(p = 0.001). Vitamin D deficiency was more com-
mon in patients with clinically significant portal
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hypertension (CSPH, HVPG ≥ 10mmHg) than in
patients without (43.5% vs. 24.4%, p = 0.025). Sig-
nificantly more deaths were observed in patients
with vitamin D deficiency (32.9%, 26/79 vs. 13.3%,
16/120; p = 0.001). COX regression found presence
of hepatocellular carcinoma (p < 0.001; HR: 5.763
95%CI:2.183–15.213), presence of CSPH (p = 0.026;
HR: 5.487 95%CI: 1.226–24.55) and Child–Pugh stage
C (p = 0.003; HR:5.429 95%CI: 1.771–16.638) as inde-
pendent risk factors for mortality. Furthermore we
could show a tendency towards group vitamin D de-
ficiency being an independent risk factor (p = 0.060;
HR: 1.86 95%CI:0.974–3.552).
Conclusions Vitamin D levels progressively decrease
in more advanced Child stages and in patients with in-
creasing HVPG. Vitamin D deficiency might be a valu-
able predictor of mortality in cirrhosis.
Keywords Vitamin D · Cirrhosis · Mortality · Liver
dysfunction · Portal hypertension
Abbreviations
VIT-D 25-OH-vitamin D3
HVPG Hepatic venous pressure gradient
CPS Child–Pugh score
CLD Chronic liver disease
CSPH Clinical significant portal hyperten-
sion
D-DEF VIT-D levels <10 ng/ml




HCV Hepatitis C virus
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HBV Hepatitis B virus
SBP Spontaneous bacterial peritonitis
DBP D-binding protein
Introduction
Liver cirrhosis is the cause of around 170,000 deaths
per year in Europe, whereas liver cancer is responsible
for around 47,000 deaths per year in the EU [1], while
a recent report suggests that even this might be an
underestimation [2]. There are several risk factors for
developing complications of cirrhosis such as ascites,
hepatic encephalopathy, and GI bleeding. Portal hy-
pertension is the triggering factor for those complica-
tions most of the time since it decreases liver function
and therefore encourages complications to begin [3].
The liver plays a crucial role in the biosynthesis of
active vitamin-D3 (i. e., calcitriol or 1,25-OH vitamin-
D3) via hydroxylation to 25-OH-vitamin-D3. Although
the final hydroxylation step to produce 1,25-OH-vi-
tamin-D3 is done in the kidney, 25-OH-vitamin-D3
(= VIT-D)—as synthesized by the liver—is the most
commonly used biomarker to measure vitamin-D sta-
tus in patients, given its half-life [4]. Other than that
25-OH-vitamin-D3 is also a key modulator of bone
growth and remodeling [5].
In a large Austrian multicenter study, up to 42%
of patients were found with VIT-D levels <20 ng/ml
[6]. Various studies have shown that VIT-D deficiency
(defined as VIT-D < 20ng/ml in those studies) has an
even higher prevalence in patients with CLD (chronic
liver disease) ranging from 64 to 92% [7–9]. Especially
in patients with cirrhosis VIT-D deficiency seems to
be seen with a significant higher prevalence than in
those without shown in a study performed by Fisher
et al. [8] where 86% of cirrhotic patients had VIT-
D deficiency compared to only 49% without cirrho-
sis. Also an inverse correlation between VIT-D status
and severity of the liver disease was found by show-
ing that patients with Child–Pugh score C had signif-
icantly lower mean VIT-D levels that those patients
found with Child–Pugh score A (9.0 ± 4.0 in CPS C vs.
18.3 ± 6.7 ng/ml in CPS A).
Four studies using different definitions for VIT-D
deficiency have evaluated the relationship between
VIT-D levels of cirrhotic patients and mortality; sig-
nificant correlations were found. However, conflicting
results regarding the cut-off serum level for VIT-D as
an independent risk factor for mortality were reported
[10–13].
The aim of this study was to investigate how VIT-D
influences mortality in a large cohort of patients and
especially if it stands as an independent risk factor for
mortality since the four studies performed reported
conflicting results. Furthermore as portal hyperten-
sion is the main risk factor in the course of patients
with cirrhosis we investigated the HVPG and its corre-
lation with VIT-D levels to find whether VIT-D could




In this retrospective multicenter study 199 patients
diagnosed with liver cirrhosis that had VIT-D level
available were included. A total of 100 consecutive
patients were included from the Medical University of
Graz and 99 consecutive patients were included from
the Medical University of Vienna. Inclusion criteria
were the following: available VIT-D level at time of
study inclusion, available Child–Pugh score, available
MELD score [14], no VIT-D supplementation of any
kind at study inclusion and available follow-up for
mortality. VIT-D levels were measured with routine
clinical analyses in all patients during outpatient vis-
its or administration to the ward. All patients have
been diagnosed with cirrhosis based on either clinical,
radiological parameters or on liver histology. Supple-
mentation of VIT-D after study inclusion was left to
the discretion of the physician following the patient
in routine care and was not part of the study. Pa-
tients that underwent liver transplantation were cen-
sored at the day of transplantation. Patients selected
for HVPG were cirrhotic patients routinely scheduled
for response guided NSBB therapy or risk assessment
prior to liver resection.
Measurement of 25-OH-vitamin D
Blood used for analysing 25-OH-vitamin-D3 was
drawn during routine blood-analysis when patients
visited the outpatient clinic or at the ward. Chemi-
luminescence Immunoassay was used for exact mea-
surement of 25-OH-vitamin-D3 (DiaSorinTM, Liaision
XL, Saluggia, Italy). Reference range was 30–100ng/ml.
Vitamin D deficiency is defined as 25-OH-vitamin-D3
levels below 20 ng/ml [15–18] although several stud-
ies used different definitions of deficiency and took
levels <10 ng/ml as deficient [12, 19]. Insufficiency is
defined as 20–30ng/ml [15–18] but once more sev-
eral studies already used >20 ng/ml as the cut-off for
normal VIT-D status in patients with CLD [10, 20, 21].
HVPG measurement
The right internal jugular vein was accessed un-
der ultrasound guidance and local anaesthesia with
Seldinger technique using a catheter introducer set
(8.5 F, Arrow International, Reading, PA, USA). Then
a balloon catheter (Pejcl Medicintechnik, Austria)[22]
was chosen to cannulate the liver vein via the trans-
jugular access as described previously [23]. CSPH was
defined as ≥10mmHg [24].
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Table 1 Patients characteristicswith andwithout vitaminDdeficiency












11.98 (4–31.33) – 6.41 (3.25–9.5) 17.4 (10.42–33) <0.001
Age, median (95%CI) 57 (38–69) 0.037
(r = 0.148)
56 (38–72) 58 (38–69) 0.072
Gender, n (%)
Male 147 (73.9%) 0.146
(r = –0.104)
57 (72.2%) 90 (75%) 0.742
Female 52 (26.1%) 22 (27.8%) 30 (25%) –
CPS, n (%)
A 57 (28.6%) <0.001
(r = –0.235)
11 (13.9%) 46 (38.3%) 0.001
B 68 (34.2%) 31 (39.2%) 37 (30.8%)
C 74 (37.2%) 37 (46.8%) 37 (30.8%)
HVPG, mean ± SD 16 ± 6.3a <0.001
(r = –0.360)
19 ± 6.13 14 ± 5.94 <0.001
CSPH, n (%)
Yes 156 (79.1%) 0.001
(r = –0.235)
68 (87.2%) 88 (74%) 0.025
No 41 (20.9%) 10 (12.8%) 31 (26%)
HCC, n (%)
Yes 27 (13.6%) 0.091
(r = –0.120)
10 (12.7%) 17 (14.2%) 0.835
No 172 (86.4%) 69 (87.3%) 103 (85.8%)
MELD, median (95%CI) 12 (6.43–24) 0.002
(r = –0.223)





2.2 (0.48–23.13) 1.54 (0.5–5.6) 0.007
Albumin [g/l] mean ± SD 33.9 (±6.2) <0.001
(r = 0.274)
31.8 (±5.74) 35.34 (±6.15) <0.001









69.5 (11.66–75) 32.5 (12.33–75) 0.003




294 (11–1027) 446 (22–1049) 0.109
Death, n (%) 42 (21.1%) 0.002
(r = –0.216)
26 (32.9%) 16 (13.3%) 0.001
aAvailable in 197 patients
bAvailable in 48 patients
Transient elastography
Transient elastography (Fibroscan, Echosense, France)
correlates well with grade of fibrosis/cirrhosis [25]. It
was performed in a supine position with the right arm
resting behind the head of the patient before mea-
surement of HVPG. At least 10 values were performed
for each patient and the median value was then taken
into account. Only values with an IQR/M < 30% were
taken in account for statistical analysis [26].
Statistical analysis
Continuous variables were reported as mean ± stan-
dard deviation (SD) or median (95% interquartile
range [IQR]), and categorical variables were reported
as number (n) of patients with the certain charac-
teristic (proportion of patients with the certain char-
acteristics [%]). Student t test was used for group
comparisons of normally distributed data, and the
Mann–Whitney U test where data was not normally
distributed. Pearson’s Chi-Square test or Fishers exact
test was performed to conduct group comparisons
for categorical data. The impact of VIT-D on mor-
tality incidence and transplant-free survival was ana-
lyzed using semi-parametric proportional hazard COX
models. To minimize problems of multilinearity the
following covariates were chosen: age, HCC yes/no,
CSPH, CPS, status D-DEF/D-NON-DEF. Child–Pugh
score was chosen over MELD since it covers more
aspects of cirrhosis (ascites, hepatic encephalopathy,
albumin and prothrombin-time). Patients entered
the model on the day when blood was drawn for
analysing VIT-D levels and were followed until either
(I) death (II) liver transplantation or (III) lost of fol-
low-up. Patients who received liver transplantation
10 Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with. . . K
original article
Fig. 1 aMedian25-OH-vitamin-D3 (VIT-D) levelsover groups
ofChild–Pughscore stages. bMedianVIT-D levels inpatients
with andwithout clinical significantportal hypertension (CSPH)
were censored at the day of surgery. A multiple lin-
ear regression model was used to find independent
covariates that influence absolute VIT-D levels (in-
dependent variable: absolute VIT-D levels). A binary
logistic model was conducted to find independent
risk factors of being found with VIT-D levels below
10 ng/ml (independent variable: D-DEF yes/no). Ka-
plan–Meier curves are shown for comparison of sur-
vival time in patients. Log-rank test was conducted
to find difference in mean survival times. Two sided
p values <0.05 were considered as statistically signifi-
cant. The IBM SPSS 22.0 statistic software (SPSS Inc.,
Armonk, NY, USA) was used for all statistical analysis.
Results
In total, 199 patients were included in the study. For
main patient characteristics see Table 1. We classified
patients into two groups for all statistical analyses:
VIT-D < 10 ng/ml = D-DEF and VIT-D > 10 ng/ml =
D-NON-DEF.
Vitamin D and cirrhosis
Of patients, 28.6% were found in CPS A, 34.2% in
CPS B and 37.2% in CPS C. Significant correlation
with absolute VIT-D levels was found (p < 0.001,
r = –0.251). We also compared median values in all
three groups and found significant difference (CPS A:
17 ng/ml, range 11.1–26, CPS B: 10.8 ng/ml, range
7.1–15.5, CPS C: 9.8 ng/ml, range 6.1–18.2; A vs. B
p < 0.001; A vs. C p < 0.001; B vs. C p = 0.904, see
Fig. 1a). Also absolute VIT-D levels significantly cor-
related with MELD score (p = 0.002, r = –0.223). When
separated into groups MELD score >10 vs ≤10 signif-
icant differences in median VIT-D levels were found
(11.2 ng/ml vs. 14.6 ng/ml; p = 0.013). Significant
correlation between VIT-D values and prothrombin
time values was found (p < 0.001, r = 0.305). Univari-
ate binary logistic regression (independent variable:
prothrombin time <60%/prothrombin time >60%, co-
variate: status D-DEF/D-NON-DEF) found being in
10-DEF as a risk factor for group “prothrombin time
<60%” (p = 0.002; OR: 2.528 95%CI: 1.404–4.552). Also
Mann–Whitney U test found significant differences
in median VIT-D values between the two subgroups
(“prothrombin time >60%” 14.4 ng/ml vs. “prothrom-
bin time <60%” 9.2 ng/ml; p < 0.001).
Vitamin D and portal pressure
In total, 78.4% of all patients were found with clinical
significant portal hypertension (CSPH). We found sig-
nificant correlations of absolute VIT-D with HVPG val-
ues (p < 0.001, r = –0.360) as well as presence of CSPH
(p = 0.001, r = –0.235). Also significant differences in
median VIT-D levels were found between the CSPH vs.
no-CSPH group (10.9 ng/ml vs. 16.4 ng/ml, p = 0.001,
see Fig. 1b). When comparing groups D-DEF/D-NON-
DEF significantly higher distribution of CSPH within
the D-DEF group could be found (87% of D-DEF had
CSPH vs only 74% of D-NON-DEF patients; p = 0.025).
ROC analysis found an AUC of 0.667 (p = 0.001) for the
prediction of CSPH using VIT-D.
Vitamin D and mortality
In all, 42/199 (21.1%) patients died during follow-up.
Univariate correlation analysis found the following
parameters significantly associated with death: al-
bumin (p = 0.002, r = –0.223), MELD (p = 0.006; r =
0.194), HVPG (p = 0.003, r = 0.210), CPS (p = 0.001, r =
0.238) and absolute VIT-D (p = 0.002, r = –0.216). Sig-
nificantly more patients died in group D-DEF 26/79
(= 32.9%) than in group D-NON-DEF 16/120 (= 13.3%)
(p = 0.001). Significant difference in median VIT-D
levels in groups “death” vs. “no death” was found (p =
0.002; 7.95 ng/ml [4–32.3] vs. 12.8 ng/ml [4.1–31.3]).
COX regression (covariates: age, HCC yes/no, CSPH,
CPS, status D-DEF/D-NON-DEF) found presence of
HCC (p < 0.001; HR: 5.763 95%CI: 2.183–15.213),
K Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with. . . 11
original article
Fig. 2 Kaplan–Meier curve shown for all patients separated in
groupswithvitamin-D-deficiency (D-DEF)andwithout (D-NON-
DEF)
Fig. 3 Kaplan–Meier curve shown for patientswith (a) and
without (b) clinical significantportal hypertension (CSPH) sep-
arated ingroupswith vitamin-Ddeficiency (D-DEF) andwithout
(D-NON-DEF)
presence of CSPH (p = 0.026; HR: 5.487 95%CI:
1.226–24.55) and CPS C (p = 0.003; HR:5.429 95%CI:
1.771–16.638) as independent risk factors for mor-
tality. A trend towards being in group D-DEF could
be seen (p = 0.060; HR: 1.86 95%CI: 0.974–3.552).
Kaplan–Meier curve found significant a difference in
survival in groups D-DEF/D-NON DEF (p = 0.001, see
Fig. 2). Furthermore we analyzed subgroups and the
influence of D-DEF status in their survival (see Figs. 3
and 4). ROC analysis determined an AUC of 0.653
(p = 0.002) for the predicting value of absolute VIT-D
levels for death.
Vitamin D and transient elastography
A total of 48 patients had valid (IQR < 30% of total kPa)
TE tracings. Significant different values were found
in groups D-DEF/D-NON-DEF (Table 1). Correlation
analysis found significant correlation between abso-
lute VIT-D values and stiffness (p = 0.003, r = –0.425).
Multivariate analysis
Linear regression (independent variable: absolute
VIT-D values; covariates model 1: age, HCC, CSPH,
MELD; model 2: age, HCC, CSPH, CPS) found CSPH
as an independent risk factor for low absolute VIT-D
levels in both models(model 1: p = 0.017, model 2: p =
0.035). Multivariate analysis found that patients found
with CPS B (p = 0.004; OR: 3.317 95%CI: 1.466–7.504)
and CPS C (p = 0.001; OR:4.091 95%CI:1.836–9.117)
are at higher risk for being found with VIT-D levels
below <10 ng/ml.
Discussion
Our study investigated the correlation of Vitamin D
in portal hypertension (documented by HVPG) and
its predictive value in patients with liver cirrhosis
in a large cohort of patients. We could show up
to 94% of patients with liver cirrhosis suffer from
VIT-D deficiency when taking >30 ng/ml as normal
level, whereas 76.4% where found deficient when
taking <20 ng/ml as the cut-off and 40% with levels
<10 ng/ml. This results are in line with the literature
when 20ng/ml was taken as a cut-off; Stokes et al.
[11] reported that 86% of cirrhotic patients were defi-
cient and a recent study found 68.9% of patients with
VIT-D < 10 ng/ml [13]. Another study performed in
Austria by Putz-Bankuti et al. [10] found 71% defi-
cient (<20 ng/ml) patients so the real number might
be somewhere around 80%. Those results also fit the
literature for patients with chronic liver disease (CLD)
where Lange et al. [21] found 66% of chronic HCV
patients in a deficient state. Therefore it seems that
presence of cirrhosis severely increases prevalence
of VIT-D deficiency. Regarding correlation between
grade of liver dysfunction and VIT-D we found sig-
nificant differences between CPS A vs. B and A vs. C,
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Fig. 4 Kaplan–Meier curve for eachChild–Pughscore (CPS)
stage separated ingroupswith vitamin-Ddeficiency (D-DEF)
andwithout (D-NON-DEF)
and could therefore enhance the results found in
other studies [10, 13]. Regarding MELD scores we
could confirm the results found in Putz Bankuti et al.
[10] and Finkelmeier et al. [13] that absolute VIT-D
significantly correlated with MELD score.
Regarding HVPG we confirm the results found by
Trepo et al. [12] published in 2013 that higher HVPG
values are associated with low VIT-D. Furthermore
we found CSPH as an independent risk factor for low
absolute VIT-D in multivariate analysis. Also median
VIT-D levels were significantly lower in the CSPH
group (Fig. 1b) and significantly more patients with
D-DEF status were found in the CSPH group (Table 1).
We could for the first time show that VIT-D signif-
icantly inversely correlates with absolute transient
elastography values. Significant differences in median
TE values could be found in groups D-DEF/D-NON-
DEF (Table 1). This confirms the results by Trepo
et al. [12] where a significant association between
absolute VIT-D steatosis and fibrosis was found. This
underlines the possible potential value of VIT-D as
a non-invasive parameter for staging cirrhosis.
Regardingmortality significantly lowermedian VIT-
D was found in patients who died during follow-up
(p = 0.002). We also found presence of HCC, presence
of CSPH and CPS C as independent risk factors for
mortality. Although D-DEF marginally missed signifi-
cance we could show a trend towards vitamin D status
as an independent risk factor for mortality (Table 2).
Therefore our results are in line with the results found
in previous studies that VIT-D is a valuable predic-
tor for survival [10–13, 27]. We could also show that
D-DEF seems to be a good cut-off for mortality given
our Kaplan–Meier curve for all patients (Fig. 2). For
the first time we could also show that VITD seems to
be a significant factor regarding survival when ana-
lyzing subgroup of patients with CSPH and patients
with CPS B (Figs. 3 and 4). Interestingly in patients
with no CSPH and also in those with CPS A D-DEF
was not a significant factor associated with survival of
those patients; hence this could be due to their still
rather intact liver. CPS C also did not reach signifi-
cance in this subgroup analysis, but our graph fairly
shows that those patients seem to decompensate very
shortly after inclusion due to their severe liver dam-
age. Therefore it seems D-DEF is not able to predict
their outcome given their end-stage disease status.
Stokes et al. very well described the function of VIT-
D in liver disease in their review published in 2012
[4]. Reduced exogenous exposure of patients to VIT-
D sources, intestinal malabsorption of dietary VIT-
D3, reduced endogenous production of VIT-D bind-
ing protein and albumin, impaired hepatic hydrox-
ylation of 1,25-OH-vitamin D3 to 25-OH-vitamin D3
and increased catabolic removal of 25-OH-vitamin D3
are described as responsible mechanisms for the VIT-
D deficiency in cirrhosis [4]. An association between
liver-related complications and low VIT-D levels have
been shown by Trepo et al. [12], Wong GL et al. [28]
and most recently by Finkelmeier et al. [13]. Trepo
et al. described a significantly higher rate of PHT
complications (such as ascites, HE or HRS) when pa-
tients were found with VIT-D levels <10 ng/ml; hence
we chose our group D-DEF (<10ng/ml) to be able
to properly compare results. Wong et al. [28] found
that in a large prospective HBV cohort (n = 426, 11%
found with cirrhosis, 89% with CLD) patients that de-
veloped clinical events had significantly lower VIT-
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Table 2 Multivariate stepwisebackwardsCOX regression
analysis regarding factors independently associatedwith
mortality
Co-Variates p-value Hazard ratio 95%CI




CPS C 0.003 5.429 1.771–16.638
Status D-DEF 0.060 1.86 0.974–3.552
Co-variates: age, HCC yes/no, CSPH, CPS, status D-DEF/D-NON-DEF
VIT-D 25-OH-vitamin-D3, CPS Child–Pugh score , HVPG hepatic venous
pressure gradient, CSPH clinical significant portal hypertension, HCC hepa-
tocellular carcinoma, MELD model for end-stage liver disease
D levels than those who did not. Finkelmeier et al.
[13] on the other hand found that patients with di-
agnosed SBP had significant lower VIT-D levels than
those without. Hence the previous results regarding
mortality and decompensation are therefore in line
with the results found in our study. In a recently pub-
lished paper by Lai JC et al. [29] the relationship be-
tween VIT-D levels, albumin and vitamin-D binding
protein (DBP) was shown. They found that cirrhotics
with synthetic dysfunction (= albumin < 3.5 g/dl) tend
to have lower total and free VIT-D as well as DBP levels
but higher percentage of free VIT-D. They stated that
“total VIT-D is not an accurate marker of true Vita-
min D status” and furthermore proposed that “sup-
plementation may not be an adequate therapy for
bone disease in cirrhosis”. Regarding our study we
therefore propose that patients found with VIT-D un-
der 10 ng/ml should be screened and evaluated even
more tightly given the results by Lai JC et al. Hence
even though their VIT-D status might not be accu-
rate we nevertheless found increased risk for adverse
events in those lower than 10 ng/ml. Furthermore we
investigated VIT-D as a noninvasive marker for grade
of disease and prediction of mortality and did not aim
to evaluate its role in cirrhotic bone disease.
In conclusion there is a strong trend towards VIT-
D levels predicting mortality in patients with cirrhosis
and a 10 ng/ml cut-off seems to discriminate patients
at higher risk for mortality. Moreover VIT-D seems to
be an accurate marker of reflecting liver dysfunction
and is a good synthesis-related parameter. Although
we found significant results regarding the association
of VIT-D and transient elastography, given the small
number of patients, further prospective studies are
needed in that direction to prove the possible value of
a combined noninvasive screening marker. Prediction
of CSPH through VIT-D cannot be made.
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